We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

50 hedge funds and large institutions have $125M invested in ProQR Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

5.06% less ownership

Funds ownership: 60.79% → 55.73% (-5.1%)

9% less funds holding

Funds holding: 55 → 50 (-5)

42% less capital invested

Capital invested by funds: $215M → $125M (-$90.2M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
50
Holders Change
-5
Holders Change %
-9.09%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
6
Increased
16
Reduced
12
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$3.55M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.4M
3
Renaissance Technologies
Renaissance Technologies
New York
+$675K
4
ACM
Aquilo Capital Management
California
+$661K
5
OAM
Oxford Asset Management
United Kingdom
+$512K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$12.6M
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$4.55M
3
ClearBridge Investments
ClearBridge Investments
New York
-$3.91M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.13M
5
Jennison Associates
Jennison Associates
New York
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$21.5M – – –
RI
2
RTW Investments
New York
$21.3M -$177K -22,117 -0.6%
Goldman Sachs
3
Goldman Sachs
New York
$19.1M -$169K -21,215 -0.6%
Jennison Associates
4
Jennison Associates
New York
$15.1M -$1.84M -229,916 -8%
AG
5
Artal Group
Luxembourg
$7.49M – – –
SFM
6
Sphera Funds Management
Israel
$5.27M +$3.55M +445,000 +95%
ACM
7
Aquilo Capital Management
California
$4.79M +$661K +82,800 +11%
BlackRock
8
BlackRock
New York
$4.6M -$50.7K -6,350 -0.8%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$4.48M – – –
Wellington Management Group
10
Wellington Management Group
Massachusetts
$4.06M +$3.4M +426,073 +153%
KA
11
Kerrisdale Advisers
Florida
$2.68M – – –
UBS Group
12
UBS Group
Switzerland
$2.6M -$121K -15,092 -3%
DCM
13
DAFNA Capital Management
California
$1.51M – – –
Caisse de Depot et Placement du Quebec (CDPQ)
14
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$1.44M – – –
Millennium Management
15
Millennium Management
New York
$1.28M -$771K -96,494 -30%
AGA
16
Altrinsic Global Advisors
Connecticut
$1.16M – – –
OPPM
17
Opus Point Partners Management
New York
$798K – – –
State Street
18
State Street
Massachusetts
$713K +$117K +14,610 +13%
Renaissance Technologies
19
Renaissance Technologies
New York
$589K +$675K +84,500 +475%
AA
20
ALPS Advisors
Colorado
$446K -$30.9K -3,871 -5%
Citadel Advisors
21
Citadel Advisors
Florida
$380K +$183K +22,971 +53%
OAM
22
Oxford Asset Management
United Kingdom
$369K +$512K +64,083 New
FSA
23
Franklin Street Advisors
North Carolina
$346K – – –
Legal & General Group
24
Legal & General Group
United Kingdom
$323K -$88K -11,025 -16%
Swiss National Bank
25
Swiss National Bank
Switzerland
$294K +$16K +2,000 +4%
1
2 3

PRQR Hedge Fund Activity: Q3 2019 in Review

50 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2019, worth a combined $125M — down 42% from $215M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PRQR and 6 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 16 added.

The largest buyer was Sphera Funds Management, adding an estimated $3.55M. The largest seller was OrbiMed, exiting entirely with an estimated $12.6M sold.

  • 50 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2019, down from 55 in Q2 2019.
  • Funds reported $125M of ProQR Therapeutics stock for Q3 2019, down 42% quarter-over-quarter.
  • 6 funds opened new ProQR Therapeutics positions in Q3 2019 and 11 closed out, a net change of -5 holders.
  • The largest ProQR Therapeutics buyer in Q3 2019 was Sphera Funds Management, an estimated $3.55M added.
  • The largest ProQR Therapeutics seller in Q3 2019 was OrbiMed, an estimated $12.6M sold.

Based on aggregated 13F filings for Q3 2019.